| Symbols and abbreviations |
|
xxiii | |
| Contributors |
|
xxix | |
|
1 Clinical skills and assessment |
|
|
1 | (52) |
|
Epidemiology of paediatric musculoskeletal conditions |
|
|
2 | (2) |
|
History taking, physical examination, and approaches to investigation |
|
|
4 | (5) |
|
Normal variants of lower limb development |
|
|
9 | (2) |
|
The gait cycle and abnormal gait patterns |
|
|
11 | (4) |
|
Normal gait and musculoskeletal development |
|
|
15 | (3) |
|
pGALS: paediatric gait, arms, legs, spine musculoskeletal screening examination |
|
|
18 | (5) |
|
pREMS: paediatric regional examination of the musculoskeletal system |
|
|
23 | (5) |
|
Musculoskeletal ultrasound in juvenile idiopathic arthritis |
|
|
28 | (4) |
|
|
|
32 | (3) |
|
Thermography in rheumatic disease |
|
|
35 | (2) |
|
Nailfold capillaroscopy in rheumatic disease |
|
|
37 | (4) |
|
Outcome measures in paediatric rheumatology |
|
|
41 | (4) |
|
The Child Health Assessment Questionnaire (CHAQ) |
|
|
45 | (8) |
|
2 Common and important clinical problems |
|
|
53 | (76) |
|
Musculoskeletal presentations and non-accidental injury |
|
|
54 | (2) |
|
Malignancy and musculoskeletal presentations |
|
|
56 | (4) |
|
|
|
60 | (4) |
|
Bone and joint infections |
|
|
64 | (6) |
|
Infections in the immunocompromised |
|
|
70 | (6) |
|
Fractures in children and adolescents |
|
|
76 | (4) |
|
|
|
80 | (7) |
|
Pain syndromes and the assessment of pain |
|
|
87 | (5) |
|
|
|
92 | (2) |
|
Pyrexia of unknown origin |
|
|
94 | (6) |
|
Back pain in children and adolescents |
|
|
100 | (3) |
|
|
|
103 | (3) |
|
Hip pain and hip problems in children and adolescents |
|
|
106 | (11) |
|
Knee pain in children and adolescents |
|
|
117 | (4) |
|
|
|
121 | (3) |
|
|
|
124 | (5) |
|
3 Juvenile idiopathic arthritis |
|
|
129 | (38) |
|
Genetics and JIA: HLA and non-HLA/MHC associations with subtypes of JIA |
|
|
130 | (7) |
|
Immunology and aetiology of JIA |
|
|
137 | (2) |
|
|
|
139 | (2) |
|
JIA subtypes and their clinical presentations |
|
|
141 | (5) |
|
Prognostic indicators in JIA |
|
|
146 | (2) |
|
Uveitis screening in JIA: the approach to screening and guidelines |
|
|
148 | (4) |
|
Surgery in the young adult with JIA: practical issues |
|
|
152 | (3) |
|
Treatment approaches in JIA |
|
|
155 | (4) |
|
Treatment pathways in JIA |
|
|
159 | (6) |
|
Disease activity scores in rheumatoid arthritis and JIA |
|
|
165 | (2) |
|
|
|
167 | (162) |
|
|
|
|
The classification of paediatric vasculitis |
|
|
168 | (3) |
|
The epidemiology of paediatric vasculitis |
|
|
171 | (1) |
|
The investigation of primary systemic vasculitis |
|
|
172 | (2) |
|
The standard treatment of childhood vasculitis |
|
|
174 | (5) |
|
|
|
179 | (4) |
|
|
|
183 | (5) |
|
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides |
|
|
188 | (4) |
|
Polyarteritis nodosa (PAN) |
|
|
192 | (6) |
|
Cutaneous polyarteritis nodosa (cPAN) |
|
|
198 | (1) |
|
|
|
199 | (6) |
|
|
|
205 | (4) |
|
Central nervous system vasculitis in children |
|
|
209 | (5) |
|
|
|
214 | (3) |
|
Vasculitis mimics: non-inflammatory vasculopathies |
|
|
217 | (6) |
|
Juvenile systemic lupus erythematosus |
|
|
|
JSLE: epidemiology and aetiology |
|
|
223 | (3) |
|
JSLE: clinical features and diagnostic criteria |
|
|
226 | (3) |
|
Assessment of the child with JSLE and monitoring of disease activity |
|
|
229 | (3) |
|
JSLE: approach to management |
|
|
232 | (4) |
|
|
|
236 | (4) |
|
|
|
240 | (1) |
|
B-cell-targeted therapies for systemic lupus erythematosus |
|
|
241 | (7) |
|
British Isles Lupus Assessment Group (BILAG) 2004 Index |
|
|
248 | (8) |
|
SLEDAI 2000 Disease Activity Index |
|
|
256 | (2) |
|
SLICC/ACR Damage Index (paediatric) |
|
|
258 | (2) |
|
Connective tissue diseases Scleroderma |
|
|
260 | (6) |
|
|
|
266 | (9) |
|
|
|
275 | (4) |
|
Antiphospholipid syndrome (APS) |
|
|
279 | (4) |
|
|
|
283 | (5) |
|
Autoinflammatory diseases and immunodeficiency |
|
|
|
Periodic fever syndromes/autoinflammatory disease |
|
|
288 | (9) |
|
Chronic recurrent multifocal osteomyelitis |
|
|
297 | (3) |
|
|
|
300 | (5) |
|
Macrophage activation syndrome |
|
|
305 | (4) |
|
Primary immunodeficiency and rheumatological disease |
|
|
309 | (3) |
|
|
|
|
Mucopolysaccharidoses (MPS) and mucolipidoses (ML) |
|
|
312 | (6) |
|
Chromosomal abnormalities and associated musculoskeletal morbidity |
|
|
318 | (5) |
|
Arthritis and other musculoskeletal features associated with cystic fibrosis |
|
|
323 | (3) |
|
Inflammatory bowel disease and musculoskeletal features |
|
|
326 | (3) |
|
5 Bone diseases, skeletal dysplasias, disorders of collagen |
|
|
329 | (26) |
|
|
|
330 | (3) |
|
|
|
333 | (10) |
|
|
|
343 | (3) |
|
Heritable disorders of connective tissue |
|
|
346 | (9) |
|
6 Infection and immunization |
|
|
355 | (22) |
|
Tuberculosis and mycobacterial disease |
|
|
356 | (7) |
|
|
|
363 | (5) |
|
|
|
368 | (3) |
|
Varicella zoster infections |
|
|
371 | (3) |
|
Immunization schedules and the immunocompromised |
|
|
374 | (3) |
|
7 The multidisciplinary approach to management |
|
|
377 | (12) |
|
The multidisciplinary team |
|
|
378 | (2) |
|
The role of the clinical nurse specialist |
|
|
380 | (2) |
|
The role of the physiotherapist |
|
|
382 | (2) |
|
The role of the occupational therapist |
|
|
384 | (1) |
|
The role of the podiatrist |
|
|
385 | (2) |
|
|
|
387 | (2) |
|
8 Specialized therapeutic approaches |
|
|
389 | (20) |
|
Corticosteroid intra-articular injections |
|
|
390 | (3) |
|
Biologic therapies for paediatric rheumatological diseases |
|
|
393 | (6) |
|
Approvals for use of biologic therapies |
|
|
399 | (2) |
|
Medicines for children and paediatric rheumatology |
|
|
401 | (4) |
|
Haematopoietic stem cell transplantation |
|
|
405 | (4) |
|
9 British Society of Paediatric and Adolescent Rheumatology clinical guidelines and protocols |
|
|
409 | (38) |
|
BSPAR standards of care for children and young people with JIA |
|
|
410 | (2) |
|
BSPAR drug information leaflets for parents and families |
|
|
412 | (3) |
|
BSPAR guidelines for treatments used in paediatric rheumatology |
|
|
415 | (1) |
|
Non-steroidal anti-inflammatory drugs (NSAIDs) |
|
|
416 | (2) |
|
Disease-modifying anti-rheumatic drugs (DMARDs) |
|
|
418 | (5) |
|
|
|
423 | (2) |
|
|
|
425 | (2) |
|
Intravenous cyclophosphamide |
|
|
427 | (4) |
|
|
|
431 | (2) |
|
|
|
433 | (1) |
|
|
|
434 | (2) |
|
Other anti-TNF-®: adalimumab (Humira®) and infliximab (Remicade®) |
|
|
436 | (1) |
|
Anti-IL-1 treatments: anakinra (Kineret®), rilonacept (Regeneron®), and canakinumab (llaris®) |
|
|
437 | (2) |
|
|
|
439 | (1) |
|
Anti-IL-6 treatment: tocilizumab (Ro-Actemra®) |
|
|
440 | (1) |
|
Anti-B-cell therapies: rituximab (Mabthera®) |
|
|
441 | (2) |
|
Systemic corticosteroids (oral, intramuscular, and intravenous) |
|
|
443 | (2) |
|
Intra-articular corticosteroid use in JIA |
|
|
445 | (2) |
|
10 Rashes in paediatric rheumatology |
|
|
447 | (10) |
|
|
|
448 | (1) |
|
Palmar psoriasis in a patient with psoriatic JIA |
|
|
448 | (1) |
|
Nail pits and psoriasis in a patient with psoriatic JIA |
|
|
449 | (1) |
|
|
|
449 | (1) |
|
|
|
450 | (1) |
|
HSP with bilateral ankle swelling |
|
|
450 | (1) |
|
Juvenile dermatomyositis with periorbital oedema |
|
|
451 | (1) |
|
Severe juvenile dermatomyositis with anterior chest wall vasculitis---'shawl sign' |
|
|
451 | (1) |
|
Extensor surface vasculitis in juvenile dermatomyositis |
|
|
452 | (1) |
|
Subtle Gottron's papules in a patient with severe juvenile dermatomyositis |
|
|
452 | (1) |
|
Periungual erythema in undifferentiated connective tissue disease |
|
|
453 | (1) |
|
Systemic vasculitis with pyrexia, livido reticularis, vasculitic rash with skin necrosis |
|
|
453 | (1) |
|
Maculo-papular rash of Epstein-Barr virus associated with haemophagocytic lymphohistiocytosis (HLH) |
|
|
454 | (1) |
|
|
|
454 | (1) |
|
Generalized peeling in Kawasaki disease |
|
|
455 | (1) |
|
Purpura in Wegener's granulomatosis |
|
|
455 | (1) |
|
SLE associated with congenital C1q deficiency |
|
|
456 | (1) |
| Index |
|
457 | |
